U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H15NO
Molecular Weight 165.2326
Optical Activity ( + )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PSEUDOEPHEDRINE

SMILES

C[C@@]([H])([C@]([H])(c1ccccc1)O)NC

InChI

InChIKey=KWGRBVOPPLSCSI-WCBMZHEXSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796

Ephedrine (l-form) is an alkaloid, which was initially purified from Ephedra plant. The extract form Ephedra has been used in China for medicinal purposes for several thousand years. Ephedrine acts as an agonist at alpha- and beta-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. The drug crosses the blood brain barrier and stimulates the central nervous system. Ephedrine products are now banned in many countries, as they are a major source for the production of the addictive compound methamphetamine. FDA has approved ephedrine only for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Originator

Sources: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889).https://www.rcpe.ac.uk/sites/default/files/lee_0.pdf
Curator's Comment:: (+)-threo-isomer of ephedrine, q.v. Isoln from E. vulgaris: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889). Synthesis: E. Späth, R. Göhring, Monatsh. Chem. 41, 319 (1920). reference retrieved from http://www.drugfuture.com/chemdata/pseudoephedrine.html

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P07550|||Q53GA6|||Q9UCZ3
Gene ID: 154
Gene Symbol: ADRB2
Target Organism: Homo sapiens (Human)
0.359999999999999987 µM [EC50]
4.95000000000000018 null [pKi]
Target ID: P08588
Gene ID: 153
Gene Symbol: ADRB1
Target Organism: Homo sapiens (Human)
0.5 µM [EC50]
4.83000000000000007 null [pKi]
5.59999999999999964 µM [IC50]
1.17999999999999994 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AKOVAZ

Approved Use

AKOVAZ injection is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Launch Date

1461888000000
Primary
SUDAFED 24 HOUR

Approved Use

temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies; reduces swelling of nasal passages; relieves sinus pressure

Launch Date

724291200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
292 ng/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
79.4 ng/mL
22 mg single, oral
dose: 22 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EPHEDRINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
87.4 ng/mL
11 mg 3 times / day multiple, oral
dose: 11 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EPHEDRINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4346 ng × h/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.3 h
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.75 h
22 mg single, oral
dose: 22 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
EPHEDRINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.69 h
11 mg 3 times / day multiple, oral
dose: 11 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
EPHEDRINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
Health Status: unknown
Age Group: 16 years
Sex: F
Sources:
Other AEs: Rhabdomyolysis, Creatine kinase increased...
Other AEs:
Rhabdomyolysis (1 patient)
Creatine kinase increased (1 patient)
Blood myoglobin increased (1 patient)
Sources:
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Other AEs: Tension, Dry mouth...
Other AEs:
Tension (10 patients)
Dry mouth (6 patients)
Tachycardia (9 patients)
Palpitations (10 patients)
Anxiety (13 patients)
Insomnia (12 patients)
Anorexia (7 patients)
Restlessness (10 patients)
Sources:
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, 3 years
Health Status: unhealthy
Age Group: 3 years
Sex: M
Sources:
Disc. AE: Urinary retention...
AEs leading to
discontinuation/dose reduction:
Urinary retention (acute, 1 patient)
Sources:
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
unhealthy, 37 years
Health Status: unhealthy
Age Group: 37 years
Sex: F
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
720 mg 1 times / day multiple, oral
Highest studied dose
Dose: 720 mg, 1 times / day
Route: oral
Route: multiple
Dose: 720 mg, 1 times / day
Sources:
unhealthy, 38.8 years
Health Status: unhealthy
Age Group: 38.8 years
Sex: M+F
Sources:
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, 44 years
Health Status: unhealthy
Age Group: 44 years
Sex: F
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, 46 years
Health Status: unhealthy
Age Group: 46 years
Sex: F
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: F
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
unhealthy, 87 years
Health Status: unhealthy
Age Group: 87 years
Sex: M
Sources:
Other AEs: Hypertension...
Other AEs:
Hypertension (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Blood myoglobin increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
Health Status: unknown
Age Group: 16 years
Sex: F
Sources:
Creatine kinase increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
Health Status: unknown
Age Group: 16 years
Sex: F
Sources:
Rhabdomyolysis 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
Health Status: unknown
Age Group: 16 years
Sex: F
Sources:
Palpitations 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Restlessness 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Tension 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Insomnia 12 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Anxiety 13 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Dry mouth 6 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Anorexia 7 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Tachycardia 9 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
Health Status: healthy
Age Group: 24 years
Sex: M
Sources:
Urinary retention acute, 1 patient
Disc. AE
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, 3 years
Health Status: unhealthy
Age Group: 3 years
Sex: M
Sources:
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
unhealthy, 37 years
Health Status: unhealthy
Age Group: 37 years
Sex: F
Sources:
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
unhealthy, 37 years
Health Status: unhealthy
Age Group: 37 years
Sex: F
Sources:
Ischemic colitis 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, 44 years
Health Status: unhealthy
Age Group: 44 years
Sex: F
Sources:
Abdominal pain acute, 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, 44 years
Health Status: unhealthy
Age Group: 44 years
Sex: F
Sources:
Ischemic colitis 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, 46 years
Health Status: unhealthy
Age Group: 46 years
Sex: F
Sources:
Abdominal pain acute, 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, 46 years
Health Status: unhealthy
Age Group: 46 years
Sex: F
Sources:
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: F
Sources:
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: F
Sources:
Hypertension 1 patient
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
unhealthy, 87 years
Health Status: unhealthy
Age Group: 87 years
Sex: M
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Epinephrine analogues.
2001 Nov
[Separation and determination of pseudoephedrine in bufferin cold tablet by capillary electrophoresis with hydropropyl-beta-cyclodextrin as chiral selective reagent].
2001 Nov
Myocardial infarction temporally related to ephedra--a possible role for the coronary microcirculation.
2002
Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases - a novel approach of eliminating evaporation and reconstitution steps in 96-well SPE.
2002
[An open label multi-center clinical trial to evaluate the efficacy of compound pseudoephedrine [corrected] hydrochloride sustained release capsules in patients with nasal symptoms associated with common cold].
2002 Aug
Generalized dermatitis due to pseudoephedrine.
2002 Aug
Evaluation of a pseudoephedrine linker for asymmetric alkylations on solid phase.
2002 Dec 26
Pharmacological characterization of a noninvasive, chronic, experimental dog model of nasal congestion.
2002 Jan-Feb
Modifying the bitterness of selected oral pharmaceuticals with cation and anion series of salts.
2002 Jul
Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit.
2002 Jul
Erythrodermia to pseudoephedrine in a patient with contact allergy to phenylephrine.
2002 Jul-Aug
Rapid simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, and 3,4-methylenedioxyethylamphetamine in urine by solid-phase extraction and GC-MS: a method optimized for high-volume laboratories.
2002 Jul-Aug
A comparative study of the side effects between pseudoephedrine in Loratadine plus Pseudoephedrine Sulfate Repetabs Tables and loratadine + pseudoephedrine tablet in treatment of allergic rhinitis in Thai patients.
2002 Jun
Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use.
2002 Jun
Pigmented purpuric dermatosis due to pseudoephedrine.
2002 May
Pseudoephedrine as a chiral auxiliary for asymmetric Michael reactions: synthesis of 3-aryl-delta-lactones.
2002 May 30
[Bacteremia caused by coagulase-negative staphylococci: incidence, frequency of teicoplanin resistance and molecular epidemiology].
2002 Nov
A moderate dose of pseudoephedrine does not alter muscle contraction strength or anaerobic power.
2002 Nov
Enantiomeric separation of methamphetamine and related analogs by capillary zone electrophoresis: intelligence study in routine methamphetamine seizures.
2002 Nov
Enhanced enantio- and diastereoselectivity via confinement and cation binding: yang photocyclization of 2-benzoyladamantane derivatives within zeolites.
2002 Nov 29
Quantitative and structural determination of pseudoephedrine sulfate and its related compounds in pharmaceutical preparations using high-performance liquid chromatography.
2002 Nov 7
[Blood supply of the lips].
2002 Oct
[Cutaneous complications following liver transplantation: epidemiologic and clinical study in 86 patients].
2002 Oct
Enzymatic (R)-phenylacetylcarbinol production in benzaldehyde emulsions.
2002 Oct
Stereospecific inhibition of monoamine uptake transporters by meta-hydroxyephedrine isomers.
2002 Oct
Severe adverse drug reactions due to pseudoephedrine from over-the-counter medications.
2002 Sep
[Toxic dermatitis caused by pseudoephedrine: apropos of a case].
2002 Sep
Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion.
2002 Sep-Oct
Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers.
2003
Baboon syndrome due to pseudoephedrine.
2003 Apr
[Improving the medical treatment of minors who are victims of sexual assault or physical abuse: a receiving center and partnership between a psychiatric hospital and university hospital].
2003 Apr
Sensitive determination of ephedrine and pseudoephedrine by capillary electrophoresis with laser-induced fluorescence detection.
2003 Apr
Surfing, self-medicating and safety: buying non-prescription and complementary medicines via the internet.
2003 Apr
Nonpigmenting solitary fixed drug eruption caused by a Chinese traditional herbal medicine, ma huang (Ephedra Hebra), mainly containing pseudoephedrine and ephedrine.
2003 Apr
Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane.
2003 Apr 14
Separation and determination of ephedrine and pseudoephedrine by combination of flow injection with capillary electrophoresis.
2003 Jan
Physiological, subjective and performance effects of pseudoephedrine and phenylpropanolamine during endurance running exercise.
2003 Jan
Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study.
2003 Jan
Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs.
2003 Jul
Development and validation of a capillary zone electrophoresis method for the determination of ephedrine and related compounds in urine without extraction.
2003 Jul 5
Chiral analysis of amphetamine-type stimulants using reversed-polarity capillary electrophoresis/positive ion electrospray ionization tandem mass spectrometry.
2003 Jun
[Tobacco: knowledge, reasoning and opinion of high school students in Doubs. Reflections on prevention].
2003 Mar
Safety of selegiline with cold medications.
2003 Mar
Adrenaline given outside the context of life threatening allergic reactions.
2003 Mar 15
Spectrophotometric determination of binary mixtures of pseudoephedrine with some histamine H1-receptor antagonists using derivative ratio spectrum method.
2003 Mar 26
In vitro evaluation of apical microleakage following canal filling with a coated carrier system compared with lateral and thermomechanical Gutta-Percha condensation techniques.
2003 May
A comparative study of root canal preparation using FlexMaster and HERO 642 rotary Ni-Ti instruments.
2003 May
Canine model of nasal congestion and allergic rhinitis.
2003 May
Exemption of chemical mixtures containing the List I chemicals ephedrine, N-methylephedrine, N-methylpseudoephedrine, norpseudoephedrine, phenylpropanolamine, and pseudoephedrine. Final rule.
2003 May 1
Press-coating of immediate release powders onto coated controlled release tablets with adhesives.
2003 May 20
Patents

Sample Use Guides

SUDAFED® 24 HOUR TABLET, EXTENDED RELEASE; ORAL (PSEUDOEPHEDRINE HYDROCHLORIDE) 240MG
Route of Administration: Oral
Name Type Language
PSEUDOEPHEDRINE
HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
(1S,2S)-(+)-PSEUDOEPHEDRINE
Common Name English
(.ALPHA.S)-.ALPHA.-((1R)-1-(METHYLAMINO)ETHYL)BENZENEMETHANOL
Systematic Name English
(+)-(1S,2S)-PSEUDOEPHEDRINE
Common Name English
PSEUDOEPHEDRINE [VANDF]
Common Name English
ACUNASO
Brand Name English
1-(S),2-(R)-ERYTHRO-(+)-EPHEDRINE
Common Name English
BENZENEMETHANOL, .ALPHA.-((1S)-1-(METHYLAMINO)ETHYL)-, (.ALPHA.S)-
Systematic Name English
PSEUDOEPHEDRINE [INN]
Common Name English
PSEUDOEPHEDRINE [HSDB]
Common Name English
(+)-THREO-EPHEDRINE
Common Name English
PSEUDOEPHEDRINE [WHO-DD]
Common Name English
PSEUDOEPHEDRINE [MI]
Common Name English
PSEUDOEPHEDRINE [MART.]
Common Name English
EPHEDRINE HYDROCHLORIDE IMPURITY B [EP]
Common Name English
ISOEPHEDRINE, D-
Common Name English
BENZENEMETHANOL, .ALPHA.-(1-(METHYLAMINO)ETHYL)-, (S-(R*,R*))-
Systematic Name English
(+)-PSEUDOEPHEDRINE
Common Name English
PSEUDOEPHEDRINE, (+)-
Common Name English
NEODURASINA
Brand Name English
Classification Tree Code System Code
WHO-VATC QR01BA02
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
CFR 21 CFR 119.1
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
WHO-VATC QR01BA52
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
NDF-RT N0000175552
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
NCI_THESAURUS C29709
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
CFR 21 CFR 1314.20
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
WHO-ATC R01BA02
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
LIVERTOX 813
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
NDF-RT N0000000209
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
WHO-ATC R01BA52
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
CFR 21 CFR 1315.13
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
Code System Code Type Description
CAS
90-82-4
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
IUPHAR
7286
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
EPA CompTox
90-82-4
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
EVMPD
SUB10157MIG
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
DRUG BANK
DB00852
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
RXCUI
8896
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY RxNorm
FDA UNII
7CUC9DDI9F
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
INN
1061
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
MESH
D054199
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
LACTMED
Pseudoephedrine
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
RXCUI
407885
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
ALTERNATIVE
NCI_THESAURUS
C61914
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
MERCK INDEX
M9294
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
202-018-6
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
ChEMBL
CHEMBL1590
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
WIKIPEDIA
PSEUDOEPHEDRINE
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
HSDB
3177
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
PUBCHEM
7028
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY
DRUG CENTRAL
2326
Created by admin on Sat Jun 26 09:17:57 UTC 2021 , Edited by admin on Sat Jun 26 09:17:57 UTC 2021
PRIMARY